论文部分内容阅读
钾通道激活剂(如Cromakalim)是打开平滑肌细胞浆膜的新药.夜间哮喘以现有的药物常难以治疗.由于晚间单剂Cromakalim 可维持其整夜血浆高浓度,故其药物动力学曲线适于本病的治疗,现将此药的治疗效果报告如下.单剂量研究:夜间哮喘患者23(男21、女2)例,年龄19～59岁,血压正常,有再发性夜间气流阻塞(其定义为夜间或凌晨PEFR 降低大于20%),设安慰对照组,进行随机、双盲和交叉研究.Croma-kalim 的用量为0.25、0.5和1.5mg。在各自的研
Potassium channel activators, such as Cromakalim, are new drugs that open the plasma membrane of smooth muscle cells. Night-time asthma is often difficult to treat with existing medications. Since the single-dose evening-course Cromakalim maintains its overnight high blood plasma concentration, its pharmacokinetic profile is suitable The treatment of this disease, the treatment effect of this drug are reported as follows: Single-dose study: 23 patients with nighttime asthma (male 21, female 2), aged 19 to 59 years old, normal blood pressure, with recurrent nocturnal airflow obstruction Defined as a> 20% reduction in PEFR at night or in the early morning) and placebo-controlled, randomized, double-blind, and crossover studies, with Croma-kalim at 0.25, 0.5, and 1.5 mg. In their own research